SORD and type 2 diabetes mellitus: In contrast, Myr (300 mg/kg) treatment reduced aldose reductase (p < 0.01) and sorbitol dehydrogenase (p < 0.05) levels and improved glyoxalase-I level (p < 0.05) in the renal tissue homogenate of T2D rats as compared to T2D control animals (Figure 9a–c).